June 5, 2017 5:35pm
So, what will …?
Pricing in the probability of adverse performance risks … it’s already there!
Pre-open indications re-cap: 2 hits (BLUE & SGMO) and 3 miss (BLCM, JUNO and KITE)
As I had stated, “Pricing has been percolating on the low end of the spectrum. Most of the RegMed, cell therapy equities are way below I-Bank target and they still haven’t been readjusted.”
I answer one question, in which company should investors commit and keep their money.
Members only. Please login.